HbA1c change at the end of study after 26 weeks [clinicaltrials_resource:4a4b1d1f73c7eafdacc57ea6dd37e02c]

HbA1c change at the end of study after 26 weeks [clinicaltrials_resource:4a4b1d1f73c7eafdacc57ea6dd37e02c]

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:4a4b1d1f73c7eafdacc57ea6dd37e02c
Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes [clinicaltrials:NCT00737776]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

HbA1c change at the end of study after 26 weeks [clinicaltrials_resource:4a4b1d1f73c7eafdacc57ea6dd37e02c]

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:4a4b1d1f73c7eafdacc57ea6dd37e02c
Bio2RDF identifier
4a4b1d1f73c7eafdacc57ea6dd37e02c
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4a4b1d1f73c7eafdacc57ea6dd37e02c
measure [clinicaltrials_vocabulary:measure]
time frame [clinicaltrials_vocabulary:time-frame]
at the end of study after 26 weeks
description
Dose and frequency to be presc ...... the normal clinical evaluation
identifier
clinicaltrials_resource:4a4b1d1f73c7eafdacc57ea6dd37e02c
title
HbA1c change at the end of study after 26 weeks
@en
inDataset
type
label
HbA1c change at the end of stu ...... b1d1f73c7eafdacc57ea6dd37e02c]
@en